Barclays
SGMO

Barclays’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Barclays’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
1
– – ﹤0.01% 5385
2025
Q4 		$0 Hold
1
– – ﹤0.01% 5635
2025
Q3 		$1 Hold
1
– – ﹤0.01% 5452
2025
Q2 		$1 Hold
1
– – ﹤0.01% 5204
2025
Q1 		$1 Sell
1
-63,247
-100% -$67K ﹤0.01% 5231
2024
Q4 		$64.5K Buy
63,248
+63,247
+6,324,700% +$116K ﹤0.01% 4700
2024
Q3 		$1 Sell
1
-54,511
-100% -$39.9K ﹤0.01% 5265
2024
Q2 		$19.5K Sell
54,512
-167,543
-75% -$90.5K ﹤0.01% 4444
2024
Q1 		$149K Sell
222,055
-102,332
-32% -$74.2K ﹤0.01% 4264
2023
Q4 		$176K Buy
324,387
+179,036
+123% +$82.5K ﹤0.01% 4472
2023
Q3 		$87.2K Sell
145,351
-19,668
-12% -$21.1K ﹤0.01% 3642
2023
Q2 		$215K Sell
165,019
-213,997
-56% -$292K ﹤0.01% 3207
2023
Q1 		$667K Sell
379,016
-119,448
-24% -$341K ﹤0.01% 3052
2022
Q4 		$1.57M Buy
498,464
+132,924
+36% +$516K ﹤0.01% 2434
2022
Q3 		$1.79M Buy
365,540
+262,234
+254% +$1.35M ﹤0.01% 1831
2022
Q2 		$428K Buy
103,306
+38,773
+60% +$168K ﹤0.01% 2980
2022
Q1 		$374K Sell
64,533
-120,293
-65% -$715K ﹤0.01% 3080
2021
Q4 		$1.39M Buy
184,826
+71,799
+64% +$624K ﹤0.01% 2610
2021
Q3 		$1.02M Sell
113,027
-5,717
-5% -$56.5K ﹤0.01% 2779
2021
Q2 		$1.42M Sell
118,744
-132,243
-53% -$1.5M ﹤0.01% 2431
2021
Q1 		$3.15M Sell
250,987
-87,171
-26% -$1.17M ﹤0.01% 1908
2020
Q4 		$5.28M Sell
338,158
-12,269
-4% -$144K ﹤0.01% 1492
2020
Q3 		$3.31M Buy
350,427
+13,533
+4% +$146K ﹤0.01% 1695
2020
Q2 		$3.02M Buy
336,894
+71,481
+27% +$663K ﹤0.01% 1763
2020
Q1 		$1.69M Buy
265,413
+30,941
+13% +$230K ﹤0.01% 2435
2019
Q4 		$1.96M Buy
234,472
+19,540
+9% +$180K ﹤0.01% 3015
2019
Q3 		$1.94M Sell
214,932
-99,659
-32% -$1.12M ﹤0.01% 2906
2019
Q2 		$3.39M Buy
314,591
+154,909
+97% +$1.65M ﹤0.01% 2290
2019
Q1 		$1.52M Buy
159,682
+98,044
+159% +$1M ﹤0.01% 2901
2018
Q4 		$708K Sell
61,638
-16,336
-21% -$203K ﹤0.01% 3465
2018
Q3 		$1.32M Sell
77,974
-41,765
-35% -$635K ﹤0.01% 3350
2018
Q2 		$1.7M Buy
119,739
+27,079
+29% +$450K ﹤0.01% 2723
2018
Q1 		$1.76M Buy
92,660
+11,775
+15% +$252K ﹤0.01% 2593
2017
Q4 		$1.33M Buy
80,885
+46,230
+133% +$688K ﹤0.01% 2828
2017
Q3 		$520K Buy
34,655
+647
+2% +$7.15K ﹤0.01% 3585
2017
Q2 		$299K Sell
34,008
-9,275
-21% -$59.5K ﹤0.01% 4007
2017
Q1 		$226K Sell
43,283
-2,540
-6% -$10.2K ﹤0.01% 4190
2016
Q4 		$140K Buy
45,823
+6,680
+17% +$24.3K ﹤0.01% 4507
2016
Q3 		$181K Buy
39,143
+22,844
+140% +$116K ﹤0.01% 4037
2016
Q2 		$94K Sell
16,299
-1,864
-10% -$11.9K ﹤0.01% 4445
2016
Q1 		$109K Buy
18,163
+4,063
+29% +$24.4K ﹤0.01% 4289
2015
Q4 		$126K Sell
14,100
-8,070
-36% -$62.2K ﹤0.01% 4251
2015
Q3 		$111K Sell
22,170
-6,105
-22% -$50.3K ﹤0.01% 4561
2015
Q2 		$311K Sell
28,275
-30,262
-52% -$390K ﹤0.01% 3848
2015
Q1 		$879K Sell
58,537
-46,406
-44% -$718K ﹤0.01% 3104
2014
Q4 		$1.57M Buy
104,943
+21,077
+25% +$256K ﹤0.01% 2750
2014
Q3 		$838K Buy
83,866
+35,018
+72% +$457K ﹤0.01% 3514
2014
Q2 		$733K Sell
48,848
-12,983
-21% -$187K ﹤0.01% 3629
2014
Q1 		$1.11M Sell
61,831
-38,944
-39% -$751K ﹤0.01% 3135
2013
Q4 		$1.31M Buy
100,775
+88,552
+724% +$1.02M ﹤0.01% 3095
2013
Q3 		$122K Sell
12,223
-12,518
-51% -$124K ﹤0.01% 5466
2013
Q2 		$193K Buy
+24,741
New +$216K ﹤0.01% 5214

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Barclays's SGMO Position: Q1 2026 in Review

Barclays held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5385.

Barclays first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.28M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Barclays held 1 share of SANGAMO THERAPEUTICS INC worth $0 as of Q1 2026.
  • Barclays left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #5385 holding.
  • Barclays first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Barclays's SANGAMO THERAPEUTICS INC position peaked at $5.28M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.